Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation

BACKGROUND: Adriamycin (ADR) is widely used in the clinical chemotherapy against breast cancer. But its efficacy is strongly limited due to the acquisition of multidrug resistance (MDR). Therefore, acquisition of the resistance to ADR is still a major cause of chemotherapy failure in breast cancer p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Zhou, Qianqian, Song, Chao, Liu, Xiaoqiu, Qin, Hao, Miao, Lixia, Zhang, Xuesen
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6331075/
https://ncbi.nlm.nih.gov/pubmed/30666159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S191353
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars